Currently Viewing:
ACOG Annual Clinical and Scientific Meeting
Making Sense of MACRA in the OB/GYN Practice
April 22, 2018
Making the New Postpartum Visit a Gateway to Long-Term Health
April 27, 2018
From Coverage to Culture, Researchers Discuss Barriers to Long-Acting Contraception
April 28, 2018
Rear Admiral Dr Wanda Barfield: How CDC's LOCATe Tool Assesses Risk-Appropriate Care
April 28, 2018
Dr Mary Norine Walsh on Being Your Own Advocate
April 28, 2018
Obstetricians Are Well-Positioned to Diagnose, Treat Postpartum Depression, Speakers Say
April 28, 2018
Results on Brexanolone IV for Postpartum Depression Shared at ACOG
April 28, 2018
Former Ambassador Nancy Brinker on Bringing the Breast Cancer Conversation to the Forefront
April 29, 2018
Dr Curtis Lowery on Technology's Place in the Future of Healthcare
April 29, 2018
USPSTF Session Brings Lively Comments on Link Between Ratings, Coverage
April 30, 2018
Dr John Schorge on Palliative Care Practices in Ovarian Cancer
April 30, 2018
Dr Jamie Bakkum-Gamez Discusses the Importance of Enhanced Recovery Pathways
April 30, 2018
Dr Haywood Brown on the Importance of Postpartum Follow-Up
May 15, 2018
Dr Mary Norine Walsh on the Rise of Maternal Mortality in the United States
May 16, 2018
Former Ambassador Nancy Brinker on the Future of the Susan G. Komen Foundation
May 17, 2018
Dr Curtis Lowery: How Technology Can Lower Costs for OB/GYN Patients
May 18, 2018
Dr Curtis Lowery: The ANGELS Program and How It Benefits Patients
May 29, 2018
Dr Mary Norine Walsh Discusses Risks for Pregnant Women With Hypertension
May 30, 2018
Rear Admiral Dr Wanda Barfield Provides an Overview of the Biggest Challenges Neonatologists Face
June 13, 2018
Dr Curtis Lowery on How His Practice Uses Technology to Benefit Patients
June 15, 2018
Currently Reading
Dr Jamie Bakkum-Gamez Discusses the Importance of Genetic Testing After Ovarian Cancer Diagnosis
June 16, 2018
Dr Mary Norine Walsh on Who Is at High Risk for Peripartum Cardiomyopathy
June 21, 2018
Dr Haywood Brown on the Alliance for Innovation in Maternal Health
June 23, 2018
Rear Admiral Dr Wanda Barfield on Perinatal Morbidity and Mortality
June 25, 2018

Dr Jamie Bakkum-Gamez Discusses the Importance of Genetic Testing After Ovarian Cancer Diagnosis

Jamie Bakkum-Gamez, MD, associate professor of obstetrics and gynecology and Gynecologic oncologist at Mayo Clinic, talks about the importance of a patient receiving genetic counseling after an ovarian cancer diagnosis. 


Jamie Bakkum-Gamez, MD, associate professor of obstetrics and gynecology and Gynecologic oncologist at Mayo Clinic, talks about the importance of a patient receiving genetic counseling after an ovarian cancer diagnosis. 

Transcript:

Why is genetic counseling so important after a patient is diagnosed with ovarian cancer?

Thank you for asking this question I think this is really, really important. A lot of patients and providers don't realize that ovarian cancer has a huge genetic component as far as the causes of it. About 20% of women who are diagnosed with an ovarian cancer actually have a gene mutation that caused it. When I say gene mutation, I mean something that they inherited, something that they could potentially pass onto their children, or be sharing with a sibling. 

Ovarian cancer is one of the most lethal cancers that a woman can be diagnosed with. In fact, 75% of the time it's diagnosed at an advanced stage. We don't have a screening test for it so picking it up early is really by luck or by chance. In women who are diagnosed with advanced stage, the liklihood of them being alive at 5 years is around 60%– again, that is because this is a highly lethal disease. 

Women who are diagnosed with an ovarian cancer should be seen by a genetic counselor. Basically what will happen when they're seen by a genetic counselor is that the genetic counselor will go through their family history, personal history, and look for other signs that may indicate a genetic mutation that caused the cancer. 

So, ovarian cancer tends to travel with breast cancer, so it's important for women to know that a strong family history of breast and/or ovarian cancer should prompt genetic counseling. The National Comprehensive Cancer Network [NCCN] basically has guidelines for when women should be referred for genetic counseling. A personal diagnosis of ovarian cancer is all you need to be recommended for genetic counseling. 

The Society of Gynecologic Oncology also has a statement supporting the fact that women should be referred for genetic counseling if they have this diagnosis. At Mayo Clinic, in 2015, we looked at our genetic counseling referral rates for women with ovarian cancer diagnosis. It was a quality improvement project actually, and we defined what our current rate was, and it was 20%. Which really– we weren't compliant then essentially with NCCN guidelines. And so we implemented a bundled approach that included patient education, order sets and referral guideline implementation into the electronic medical record for each woman diagnosed with ovarian cancer. 

Patient education– not just through check lists of risks factors but also education in the form of a short video that they watched in the hospital after their surgery. What we were able to do is we were able to increase our rates of referral from our pre or historic referral rate which by the time we implemented the project we actually moved the needle a little bit already, we were at 40% referral. But with our quality improvement project, we actually went up to 77% referral rate. 

So, we're continuing to try to refine that because ideally we do want to chase 100% because all of these women really should be seen for genetic counseling and offered genetic testing.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!